FINWIRES · TerminalLIVE
FINWIRES

HKG:2196

9 stories mentioning HKG:2196

Every FINWIRES story that references HKG:2196, newest first.

Asia

Fosun Pharmaceutical to Invest 414 Million Yuan in Xingyao Kunze's Series B Funding Round

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196), through subsidiary Fosun Pharma Industry, plans to invest 414.4 million yuan to participate in the Series B financing of Xingyao Kunze, according to a Wednesday filing on the Shanghai bourse.Xingyao Kunze develops drugs for liver diseases. Its pipeline products are HT-101 and HT-102, and the combination of these drugs.After the completion of the funding round, Fosun Pharma Industry is expected to own 20.9% of Xingyao Kunze.The pharmaceutical company's Hong Kong shares fell by less than 2% during the afternoon trade.

HKG:2196SHA:600196
Asia

Fosun Pharma Gets Registration Nod for Infection Drug in China

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Yaopharma obtained drug registration approval for the Levofloxacin Injection from China's National Medical Products Administration, according to a Thursday filing with the Hong Kong bourse.The approved indication is for various mild, moderate, and severe infections caused by susceptible bacteria, including pneumonia, acute bacterial sinusitis, skin infections urinary tract infections, and more.

HKG:2196SHA:600196
Asia

Fosun Pharma Secures $60 Million Option for Alzheimer's Drug

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) subsidiary Fosun Pharma Industrial signed an exclusive option agreement with South Korea's AriBio for AR1001, an oral drug candidate for early Alzheimer's disease.The unit will pay a $60 million option fee and can exercise the license within 90 days after receiving topline data from an ongoing global Phase III trial.If exercised, Fosun Pharma Industrial will pay up to $180 million in upfront and regulatory milestones, plus tiered royalties.Shares of Shanghai Fosun Pharmaceutical were down 1% in recent trade on the Shanghai and Hong Kong bourses.

HKG:2196SHA:600196
Asia

Fosun Pharma's Unit's Registration Application for Blood Stasis Syndrome Drug Accepted in China

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Hebei Wanbang Folon Pharmaceutical's drug registration application for Tao Hong Si Wu Tang Granules was accepted by China's National Medical Products Administration.The drug is intended to be used for blood deficiency and blood stasis syndrome, according to a Wednesday Hong Kong bourse filing.

HKG:2196SHA:600196
Asia

Fosun Pharma Unit Gets China Approval for Antidepressant Application

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit's drug registration application for Venlafaxine Hydrochloride Sustained-release Tablets obtained approval from China's National Medical Products Administration.The approved indication for the drug, developed by Fosun Pharma (Xuzhou), is to treat depression and generalized anxiety disorder, according to a Friday Hong Kong bourse filing.

HKG:2196SHA:600196
Asia

Fosun Pharma Unit Gets China Nod for Acute Heart Failure Drug Registration

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Yaopharma's drug registration application for the Sodium Nitroprusside Injection was approved by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The approved indication is for hypertensive emergencies and acute heart failure.

HKG:2196SHA:600196
Asia

Fosun Pharmaceutical Reports 14% Higher Profit in Q1

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) logged a 14% rise in its attributable profit for the first quarter of 2026 to 870.8 million yuan from 764.8 million yuan a year earlier, according to a Hong Kong bourse filing Tuesday.The pharmaceutical company's Hong Kong shares fell nearly 2% in late morning trade Wednesday.Earnings per share were 0.33 yuan, compared with 0.29 yuan in the prior year.Operating revenue gained nearly 7% to 10.1 billion yuan, figures showed.

HKG:2196SHA:600196
Asia

Fosun Pharma Unit Gets China Nod for Amyloidosis Drug Trial

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Fosun Kairos (Shanghai) Biological Technology obtained approval for a phase I/II clinical trial of FKC289 injection from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The drug will be tested for the treatment of primary light chain amyloidosis and membranous nephropathy.The subsidiary will begin the trial once conditions are met.

HKG:2196SHA:600196
Asia

Fosun Pharma Unit Gets China Nod to Register Analgesia Drug

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Yaopharma's drug registration application of Flurbiprofen Axetil Injection was approved by China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The approved indication is for post-surgical and cancer-related analgesia.

HKG:2196SHA:600196